Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)

NCT05476497 is registered in ClinicalTrials.gov with Allergy Therapeutics as lead sponsor.

NCT NCT05476497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05476497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)
Lead sponsor
Allergy Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 17, 2022
Completion date
November 30, 2026
Enrollment
46 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy